N E Kay|P D Markham - JoVE Visualize

Showing results (121-130 of 183) with videos related to

Pageof 19

Sort By:

Clinical and Diagnostic Laboratory Immunology|July 1, 1994

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?K Kuus-Reichel, L S Grauer, L M Karavodin, et al.

Science (New York, N.Y.)|February 17, 1984

Lymphokine production by cultured human T cells transformed by human T-cell leukemia-lymphoma virus-IS Z Salahuddin, P D Markham, S G Lindner, et al.

Journal of Virology|June 1, 1995

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1P Lusso, F Cocchi, C Balotta, et al.

Nature|January 26, 1989

Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6P Lusso, B Ensoli, P D Markham, et al.

Leukemia & Lymphoma|January 1, 1995

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.

Blood|August 1, 1982

Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activityR T Perri, N E Kay, J McCarthy, et al.

The Journal of Clinical Investigation|July 1, 1979

Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 1, 1985

Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sourcesS Z Salahuddin, P D Markham, M Popovic, et al.

The American Journal of Pathology|June 17, 1998

Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion developmentF Samaniego, P D Markham, R Gendelman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot studyM J O'Connell, J P Colgan, M M Oken, et al.

Pageof 19

Showing results (121-130 of 183) with videos related to

Sort By:

Pageof 19

Clinical and Diagnostic Laboratory Immunology|July 1, 1994

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?K Kuus-Reichel, L S Grauer, L M Karavodin, et al.

Science (New York, N.Y.)|February 17, 1984

Lymphokine production by cultured human T cells transformed by human T-cell leukemia-lymphoma virus-IS Z Salahuddin, P D Markham, S G Lindner, et al.

Journal of Virology|June 1, 1995

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1P Lusso, F Cocchi, C Balotta, et al.

Nature|January 26, 1989

Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6P Lusso, B Ensoli, P D Markham, et al.

Leukemia & Lymphoma|January 1, 1995

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.

Blood|August 1, 1982

Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activityR T Perri, N E Kay, J McCarthy, et al.

The Journal of Clinical Investigation|July 1, 1979

Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 1, 1985

Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sourcesS Z Salahuddin, P D Markham, M Popovic, et al.

The American Journal of Pathology|June 17, 1998

Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion developmentF Samaniego, P D Markham, R Gendelman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot studyM J O'Connell, J P Colgan, M M Oken, et al.

Pageof 19